WO2010030670A3 - Compositions and methods for the prevention of oxidative degradation of proteins - Google Patents

Compositions and methods for the prevention of oxidative degradation of proteins Download PDF

Info

Publication number
WO2010030670A3
WO2010030670A3 PCT/US2009/056365 US2009056365W WO2010030670A3 WO 2010030670 A3 WO2010030670 A3 WO 2010030670A3 US 2009056365 W US2009056365 W US 2009056365W WO 2010030670 A3 WO2010030670 A3 WO 2010030670A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
prevention
compositions
methods
oxidation
Prior art date
Application number
PCT/US2009/056365
Other languages
French (fr)
Other versions
WO2010030670A2 (en
Inventor
Junyan A. Ji
Yuchang John Wang
Boyan Zhang
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Priority to CN2009801445283A priority Critical patent/CN102209554A/en
Priority to CA2734275A priority patent/CA2734275A1/en
Priority to EP09792371A priority patent/EP2334323A2/en
Priority to AU2009291865A priority patent/AU2009291865A1/en
Priority to MX2011002372A priority patent/MX2011002372A/en
Priority to BRPI0918978A priority patent/BRPI0918978A2/en
Priority to JP2011526940A priority patent/JP5705115B2/en
Publication of WO2010030670A2 publication Critical patent/WO2010030670A2/en
Publication of WO2010030670A3 publication Critical patent/WO2010030670A3/en
Priority to IL211234A priority patent/IL211234A0/en
Priority to IL229180A priority patent/IL229180A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to pharmaceutical formulations comprising a protein and free methionine in combination with one or more compounds capable of preventing the oxidation of aromatic amino acid residues within a protein. More specifically, the invention relates to stabilized, pharmaceutically effective preparations of oxidation-sensitive therapeutic agents. The invention further relates to a method of inhibiting the oxidation of such therapeutic agents.
PCT/US2009/056365 2008-09-10 2009-09-09 Compositions and methods for the prevention of oxidative degradation of proteins WO2010030670A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN2009801445283A CN102209554A (en) 2008-09-10 2009-09-09 Compositions and methods for the prevention of oxidative degradation of proteins
CA2734275A CA2734275A1 (en) 2008-09-10 2009-09-09 Compositions and methods for the prevention of oxidative degradation of proteins
EP09792371A EP2334323A2 (en) 2008-09-10 2009-09-09 Compositions and methods for the prevention of oxidative degradation of proteins
AU2009291865A AU2009291865A1 (en) 2008-09-10 2009-09-09 Compositions and methods for the prevention of oxidative degradation of proteins
MX2011002372A MX2011002372A (en) 2008-09-10 2009-09-09 Compositions and methods for the prevention of oxidative degradation of proteins.
BRPI0918978A BRPI0918978A2 (en) 2008-09-10 2009-09-09 compositions and methods the prevention of oxidative degradation of proteins
JP2011526940A JP5705115B2 (en) 2008-09-10 2009-09-09 Compositions and methods for prevention of oxidative degradation of proteins
IL211234A IL211234A0 (en) 2008-09-10 2011-02-15 Compositions and methods for the prevention of oxidative degradation of proteins
IL229180A IL229180A0 (en) 2008-09-10 2013-10-31 Compositions and methods for the prevention of oxidative degradation of proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9587808P 2008-09-10 2008-09-10
US61/095,878 2008-09-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP12178248.6A Previously-Filed-Application EP2684570A1 (en) 2008-09-10 2009-09-09 Compositions and methods for the prevention of oxidative degradation of proteins

Publications (2)

Publication Number Publication Date
WO2010030670A2 WO2010030670A2 (en) 2010-03-18
WO2010030670A3 true WO2010030670A3 (en) 2010-05-06

Family

ID=41351722

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/056365 WO2010030670A2 (en) 2008-09-10 2009-09-09 Compositions and methods for the prevention of oxidative degradation of proteins

Country Status (11)

Country Link
US (2) US20100068210A1 (en)
EP (2) EP2334323A2 (en)
JP (2) JP5705115B2 (en)
KR (1) KR20110076918A (en)
CN (2) CN103599541A (en)
AU (1) AU2009291865A1 (en)
BR (1) BRPI0918978A2 (en)
CA (1) CA2734275A1 (en)
IL (2) IL211234A0 (en)
MX (1) MX2011002372A (en)
WO (1) WO2010030670A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037449T2 (en) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Combination of an insulin and a glp-1 agonist
AR080669A1 (en) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION INCLUDING A GLP-1 AGONIST, AN INSULIN AND METIONIN
WO2011058082A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist and methionine
EP2364690A1 (en) * 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
EP3513810A1 (en) * 2010-03-22 2019-07-24 F. Hoffmann-La Roche AG Compositions and methods useful for stabilizing protein- containing formulations
ES2606554T3 (en) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the manufacture of a medication for the treatment of type 2 diabetes mellitus
EP2637711B1 (en) * 2010-11-10 2024-03-27 ProKidney Injectable formulations for organ augmentation
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103561757B (en) 2011-06-07 2016-01-06 旭化成制药株式会社 High-purity is containing PTH freeze-dried preparation and manufacture method thereof
BR112014004726A2 (en) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland pharmaceutical combination for use in glycemic control in type 2 diabetes patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EA034347B1 (en) * 2011-10-26 2020-01-30 Амген Инк. Method of inactivating viruses in preparing antibodies
TWI780236B (en) 2013-02-04 2022-10-11 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP6450364B2 (en) * 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド Chimeric cytokine formulations for ocular delivery
SG10201705525VA (en) * 2013-03-13 2017-08-30 Genentech Inc Formulations with reduced oxidation
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
SI2968467T1 (en) * 2013-03-13 2020-11-30 F. Hoffmann-La Roche Ag Formulations with reduced oxidation
US20140314778A1 (en) * 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
AR095348A1 (en) 2013-03-15 2015-10-07 Genentech Inc CELL CULTURE MEDIA AND ANTIBODY PRODUCTION METHODS
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN105899190B (en) 2014-01-09 2022-06-14 赛诺菲 Stabilized pharmaceutical formulations of insulin aspart
PL3229828T3 (en) 2014-12-12 2023-07-31 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
WO2017049205A2 (en) * 2015-09-18 2017-03-23 Amunix Operating Inc. Growth hormone formulation
CN114706271A (en) 2016-03-31 2022-07-05 富士胶片株式会社 Processing liquid for semiconductor manufacturing and pattern forming method
US11142553B2 (en) 2016-11-29 2021-10-12 Spiber Inc. Protein composition, method for producing same and method for improving heat stability
EP3684412B1 (en) * 2017-09-22 2024-02-14 Immunogen, Inc. Methods of preventing methionine oxidation in immunoconjugates
WO2019059302A1 (en) * 2017-09-22 2019-03-28 旭化成ファーマ株式会社 Teriparatide-containing liquid pharmaceutical composition having excellent stability
JP2019156805A (en) * 2018-03-16 2019-09-19 ナガセ医薬品株式会社 Container filling human pth(1-34) liquid pharmaceutical composition, and method for manufacturing the same
US20210283238A1 (en) * 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
AU2019319822A1 (en) * 2018-08-08 2021-03-18 Genentech, Inc. Use of tryptophan derivatives and L-methionine for protein formulation
JP2020052012A (en) 2018-09-28 2020-04-02 株式会社Ｌｓｉメディエンス Immunoassay reagent using insoluble carrier
CN112451652A (en) * 2020-12-07 2021-03-09 苏州智核生物医药科技有限公司 Recombinant human thyrotropin injection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1197221A1 (en) * 1999-03-01 2002-04-17 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
EP1260230A1 (en) * 2000-02-29 2002-11-27 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
ATE113846T1 (en) 1988-06-21 1994-11-15 Genentech Inc THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF MYOCARDIAL INFARCTS.
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
DE122006000006I2 (en) 1991-08-14 2011-06-16 Genentech Inc Altered immunoglobulins for specific FC epsilon receptors
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP0733207B1 (en) 1993-12-10 1997-08-27 Genentech, Inc. Methods for diagnosis of allergy and screening of anti-allergy therapeutics
JP3825798B2 (en) 1994-01-18 2006-09-27 ジェネンテク，インコーポレイテッド Method for treating parasitic infections using IgE antagonists
EP0749488A1 (en) 1994-03-03 1996-12-27 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JPH11507535A (en) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド Antibodies and antibody fragments that suppress tumor growth
DK0877626T3 (en) 1996-01-23 2002-12-30 Univ Vermont Anti-CD18 antibodies for use against stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
KR100532178B1 (en) 1996-11-27 2005-12-01 제넨테크, 인크. Humanized Anti-CD11a Antibodies
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
NZ500078A (en) 1997-04-07 2001-10-26 Genentech Inc Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
DK1860187T3 (en) 1997-05-15 2011-10-31 Genentech Inc Apo-2 receptor
DK2130554T3 (en) * 1999-02-22 2012-12-03 Univ Connecticut Albumin-free factor VIII preparations
JP3062493B1 (en) * 1999-03-19 2000-07-10 明治乳業株式会社 Bifidus factor photodegradation inhibitor
IL146954A0 (en) 1999-06-25 2002-08-14 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
IL149116A0 (en) 1999-10-29 2002-11-10 Genentech Inc Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
US6989138B2 (en) * 2000-10-24 2006-01-24 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
ATE355087T1 (en) * 2000-10-24 2006-03-15 Cis Bio Int STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS WITH A HYDROPHILIC THIOETHER OR A HYDROPHILIC 6-HYDROXY-CHROMANE
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
WO2003033658A2 (en) 2001-10-17 2003-04-24 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003208415B2 (en) 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
PL218660B1 (en) 2002-10-17 2015-01-30 Genmab As Human monoclonal antibodies against CD20
EP2301966A1 (en) 2002-12-16 2011-03-30 Genentech, Inc. Immunoglobulin variants and uses thereof
KR101412271B1 (en) 2003-05-09 2014-06-25 듀크 유니버시티 CD20-Specific Antibodies and Methods of Employing Same
AR044388A1 (en) 2003-05-20 2005-09-07 Applied Molecular Evolution CD20 UNION MOLECULES
AU2004263538B2 (en) 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
GT200600031A (en) * 2005-01-28 2006-08-29 ANTI-BETA ANTIBODY FORMULATION
JP5196654B2 (en) 2005-06-20 2013-05-15 ジェネンテック， インコーポレイテッド Compositions and methods for tumor diagnosis and treatment
US8216571B2 (en) * 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
EP3381445B1 (en) * 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
JP5731726B1 (en) 2014-06-26 2015-06-10 楽天株式会社 Information processing apparatus, information processing method, and information processing program

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1197221A1 (en) * 1999-03-01 2002-04-17 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
EP1700605A2 (en) * 1999-03-01 2006-09-13 Chugai Seiyaku Kabushiki Kaisha Lyophilized methionine-containing protein preparations stabilized over long time
EP1260230A1 (en) * 2000-02-29 2002-11-27 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time

Also Published As

Publication number Publication date
EP2334323A2 (en) 2011-06-22
KR20110076918A (en) 2011-07-06
WO2010030670A2 (en) 2010-03-18
BRPI0918978A2 (en) 2015-12-01
CA2734275A1 (en) 2010-03-18
JP2015107973A (en) 2015-06-11
US20100068210A1 (en) 2010-03-18
AU2009291865A1 (en) 2010-03-18
CN103599541A (en) 2014-02-26
MX2011002372A (en) 2011-04-04
US20130171162A1 (en) 2013-07-04
JP2012502102A (en) 2012-01-26
EP2684570A1 (en) 2014-01-15
CN102209554A (en) 2011-10-05
IL229180A0 (en) 2013-12-31
IL211234A0 (en) 2011-04-28
JP5705115B2 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
WO2010030670A3 (en) Compositions and methods for the prevention of oxidative degradation of proteins
WO2006051110A3 (en) Stable formulations of insulinoptropic peptides
WO2010130832A3 (en) Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2007134279A3 (en) Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2006051103A3 (en) Stable formulations of peptides
WO2005023866A3 (en) Peptides that inhibit complement activation
NO340679B1 (en) Pyridazine derivatives, pharmaceutical compositions comprising such and such compounds and preparations for use in therapeutically active substances for the treatment and prevention of diseases
WO2008030968A3 (en) Fusion peptide therapeutic compositions
IL195030A (en) Dpp iv inhibitor formulations
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
WO2008021088A3 (en) Salicylanilides enhance oral delivery of therapeutic peptides
WO2009075859A3 (en) Formulation of insulinotropic peptide conjugates
WO2009105774A3 (en) Amino acid inhibitors of cytochrome p450
WO2007056142A3 (en) Methods of preventing the serotonin syndrome and compositions for use therefor
EP1773369A4 (en) Pharmaceutical compositions and methods for peptide treatment
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2008053297A3 (en) Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
PL1799188T3 (en) Use of peptides as an antioxidant agent for the preparation of a cosmetic and/or pharmaceutical composition
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2007121124A3 (en) Hcv inhibitors comprising beta amino acids and their uses
AP3573A (en) Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
TWI368521B (en) A spontaneous pharmaceutical composition for treatment and prevention of proliferative diseases,uses and preparation thereof
WO2008003050A3 (en) Gallium nitrate formulations
WO2009068708A3 (en) Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980144528.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09792371

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009291865

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 211234

Country of ref document: IL

Ref document number: 2734275

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009792371

Country of ref document: EP

Ref document number: MX/A/2011/002372

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1522/CHENP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009291865

Country of ref document: AU

Date of ref document: 20090909

Kind code of ref document: A

Ref document number: 2011526940

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20117008149

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0918978

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110309